Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, News & History

AUPHNASDAQ
$16.14
Last update: Apr 24, 11:08 AM
80%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
135.66M
Investing Cash Flow (TTM)
-32.77M
Financing Cash Flow (TTM)
-106.11M
Free Cash Flow (TTM)
135.41M
Capital Expenditure (TTM)
-252.00K
Net Change in Cash (TTM)
-3.22M

Analyst Trends and Forecast

1
Nov 25
1
Dec 25
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
2.8
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$1.77B
PE Ratio (TTM)
7.80
PE Ratio (FWD)
23.15
PEG Ratio (TTM)
-
PS Ratio (TTM)
7.91
PB Ratio (TTM)
3.61
Earnings Yield % (TTM)
12.83%
Earnings Yield % (FWD)
4.32%
EV / EBITDA (TTM)
12.86
Price / EBITDA (TTM)
16.23
Price / Free Cash Flow (TTM)
16.53
Book Value / Share
$4.47

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-$13.14M
Total Cash
$80.21M
Debt to Equity
0.13
Issuance of Debt (TTM)
-$13.14M
Repayment of Debt (TTM)
-$13.14M

Key Statistics

Open
$16.03
Close
-
Volume / Avg.
356.46K / 1.05M
Day Range
$15.88 - $16.34
52 Wk Range
7.29 - 16.88
Market Cap
$2.10B
P/E Ratio
7.80
Dividend Yield
-
Exchange
NASDAQ
RSI
60
Short Interest
9.21%
Days to Cover
8.76

About

Sector
Health Care
Industry
Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for ...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Aurinia Pharmaceuticals (AUPH) stock?

A

You can purchase shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) through any online brokerage.

View our list of the best stock brokerages

Q

What is the forecast, or price target, for Aurinia Pharmaceuticals (AUPH) stock?

A

Aurinia Pharmaceuticals has a consensus price target of $15.33.

Q

What is the current price for Aurinia Pharmaceuticals (AUPH)?

A

The stock price for Aurinia Pharmaceuticals (NASDAQ: AUPH) is $16.14 last updated April 24, 2026 at 11:08 AM EDT.

Q

Does Aurinia Pharmaceuticals (AUPH) pay a dividend?

A

There are no upcoming dividends for Aurinia Pharmaceuticals.

Q

When is Aurinia Pharmaceuticals (NASDAQ:AUPH) reporting earnings?

A

Aurinia Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Aurinia Pharmaceuticals (AUPH) going to split?

A

There is no upcoming split for Aurinia Pharmaceuticals.

Q

What sector and industry does Aurinia Pharmaceuticals (AUPH) operate in?

A

Aurinia Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.